When Politics Starts Governing Other People’s Bodies There is something deeply wrong with a country when the bodies of a small minority become a public battleground for people who will never have to live in them. That is where the UK now is on transgender healthcare. A growing number of politicians, campaigners and commentators have helped turn trans people’s medical treatment into a culture war object, and the NHS is increasingly acting inside that pressure rather than above it. The result is a system where public opinion and political anxiety are shaping access to care that has been used in endocrinology and gender medicine for decades. The new NHS England review of adult transgender healthcare is a clear example. On paper, it is described as an evidence review of masculinising and feminising hormone therapy for adults. In reality, it is part of a much larger restructuring that began after the Bell case, intensified through the Cass Review, and has now expanded from youth services into adult care. NHS England has already said the findings from these reviews will feed into later consultation on gender service policy. That means this is not just an administrative exercise about waiting times. It is a reconsideration of the evidence base behind adult hormone treatment itself. That should concern anyone who thinks healthcare should be led by medicine rather than moral panic. The treatments under review are not new. International clinical standards, including the World Professional Association for Transgender Health Standards of Care Version 8, describe gender-affirming hormone therapy as part of established care pathways intended to improve psychological wellbeing, physical health and quality of life for transgender people. The aim of care is not ideological affirmation. It is relief of distress and improved health outcomes. At the same time, the NHS’s own adult gender service review by Dr David Levy found a system already in serious trouble. Waiting times are extreme, service provision is fragmented, and outcome data are inconsistently collected. In some parts of England, waits for a first appointment have stretched for years, with reporting around the Levy review indicating waits that can approach a decade or more. This is not a functioning service being calmly refined. It is a broken one being subjected to another wave of scrutiny while patients continue to wait. The second angle is the human cost. When care is delayed, narrowed or turned into a public controversy, the people living through that do not disappear. They remain in distress while their treatment becomes a talking point. That has already been visible in the youth system. Good Law Project published Freedom of Information data from the NHS-funded National Child Mortality Database showing 46 recorded suicides of trans children under 18 in England between 2019 and 2025, including 22 in 2021 to 2022. The dataset itself warns that recent years are likely an underestimate because not all child death reviews are complete. Those figures do not prove a single cause for each death. Suicide is always more complex than that. But they do show a devastating level of loss unfolding in the same period that trans healthcare was being restricted, destabilised and politicised. That is why the language of “neutral evidence gathering” rings hollow for many families and trans people. In youth care, routine puberty blocker access was removed and placed behind a research pathway. Then even that pathway became unstable. NHS England has also now said there is not enough evidence to support routine provision of masculinising and feminising hormones for children and young people going forward through the NHS children and young people’s gender service. Whatever words officials choose, the practical reality is a shrinking route to care.